Professor Thomas Thum, MD, PhD, is Director of the Institute of Molecular and Translational Therapeutic Strategies at Hannover Medical School and Visiting Professor at Imperial College London. His research focuses on cardiovascular medicine, fibrosis and the development of RNA-based therapeutics, spanning target discovery through clinical translation. He has authored more
Scientific Advisor, Advent Life Sciences Fraser is a neuropharmacologist with almost 30 years of drug discovery and early development experience across a range of therapeutic areas, including neurodegeneration, psychiatry, inflammation, gastrointestinal and dermatology. He has a wide C-suite experience in multiple biotech startups and held leadership roles at Shire, AstraZeneca,
Investment Director, Life Sciences, Bpifrance Investissements Since 2014 at Bpifrance Investissements, Benoit has been involved in a dozen investment deals and current board member positions include Alentis, Dynacure, Igyxos, Meiogenix and BrainEver. Prior to this, he gained experience in various biotech roles, co-discovered a vaccine candidate, and developed an antibody
Partner, AdBio Partners Clément Bertholet spent the first part of this carreer between life science and corporate finance. He graduated from Ecole Normale Supérieure (ENS Paris Saclay) with a major in Biology and Health and several experiences in Institut Curie and Cancer Research UK, before joining the Corps des Mines, a
Claudia Ulbrich, MD, is a serial entrepreneur and senior executive with over 25 years of experience in leading and building private and public biotech companies together with high-performing teams. Her track record includes successful multi-billion EUR exits, pharma partnerships, and IPOs. Most recently she served as CEO of Cardior Pharmaceuticals,